Previous 10 | Next 10 |
home / stock / azn / azn articles
Monday, AstraZeneca Plc (NASDAQ:PLC) released latest analysis of the results from the DUO-E Phase 3 trial of Imfinzi (durvaluma...
Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization...
Thursday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on ...
In a move outlined in his upcoming State of the Union address, President Joe Biden is pushing for an increase in the number of prescripti...
As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenom...
Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, ...
The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials ...
Monday, the FDA approved AstraZeneca Plc's (NASDAQ:AZN) Tagrisso (osimertinib) plus chemotherapy for locally advanced or metast...
Thursday, AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter 2023 sales of $12.02 billion, up 7% Y/Y (+8% at constant currency), slight...
News, Short Squeeze, Breakout and More Instantly...
2024-07-20 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...